IBTA e-News October 2018 released

By 2nd November 2018 November 28th, 2018 News archive
[31 October 2018] The IBTA's monthly e-News has been released and has emailed to all subscribers. To sign up to receive your copy, click here.

You can also read the IBTA e-News October 2018 edition in full online here.

Some of the highlights from this month's round-up:

  • A first-in-human phase 0 trial of AZD1775 in first-recurrence glioblastoma has shown that the drug penetrates the blood-brain barrier and has provided evidence of clinically-relevant activity. AZD1775 targets cancer cells and makes their DNA sensitive to damage.
  • report from the UK-based charity Brain Tumour Research has revealed some of the financial costs and impacts experienced by those who are diagnosed with a brain tumour. Results from an online survey showed the average financial loss following brain tumour diagnosis is nearly £15,000 (approx. US $19,500) per household per year - more than double the average for all cancers.
  • Sixty percent of survivors of childhood central nervous system (CNS) tumours do not achieve complete independence as adults, according to findings published in the Journal of Clinical Oncology.
  • NX Development Corp has announced the US commercial launch of Gleolan (aminolevulinic acid HCl), which is the first FDA-approved optical imaging agent for high-grade glioma (WHO grades III and IV).
  • In experiments on animals, an international team of researchers has successfully used a Zika virus vaccine to target and destroy human glioblastoma brain cancer stem cells (those cells believed to drive overall tumour growth).
  • A study published in the Journal of Rehabilitation Medicine has examined whether patients who have surgery for meningioma tumours are restricted in their participation in various activities has found that a third of patients are not able to return to work after surgery.
  • The planned enrolment of 380 patients in Tocagen’s Toca 5 pivotal phase 3 trialhas been completed approximately three months ahead of schedule, the company has announced. Toca 5 is a randomized, multi-center clinical trial evaluating the safety and efficacy of Toca 511 & Toca FC compared to standard of care in patients undergoing resection for recurrent high grade glioma.
  • It has been announced that the first glioblastoma patients have been enrolled in a phase 2 clinical trial of Kazia Therapeutics' GDC-0084. The oral drug inhibits the phosphoinositide-3-kinase (PI3K) signalling pathway, which appears to be distorted in over 85% of glioblastoma cases.

Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to nearly 6,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News every month by registering here.

To see an archive of existing e-News issues, click here.

let us know you agree to cookies

The IBTA website uses cookies to give you the best online experience in accordance with our cookies policy. If you are happy, please confirm by clicking the 'Accept' button below.